Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Alzheimer's Disease

Conditions

Alzheimer's Disease

Trial Timeline

Apr 19, 2018 → Dec 31, 2021

About Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.

Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab. is a approved stage product being developed by Yuhan for Alzheimer's Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT03441516. Target conditions include Alzheimer's Disease.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03441516ApprovedUNKNOWN

Competing Products

20 competing products in Alzheimer's Disease

See all competitors
ProductCompanyStageHype Score
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
GSK4527226AlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
simufilamCassava SciencesPhase 2
44
Remternetug + PlaceboEli LillyPhase 3
77
solanezumabEli LillyPhase 2
52
LY2886721 + PlaceboEli LillyPhase 1
33
Gantenerumab + Gantenerumab + Gantenerumab + PlaceboChugai PharmaceuticalPhase 1
33
FK962Astellas PharmaPhase 2
52
ASP0777 + PlaceboAstellas PharmaPhase 1
33
Elenbecestat + PlaceboEisaiPhase 3
77
DonepezilEisaiApproved
85
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)EisaiPhase 3
77
Donepezil hydrochlorideEisaiPhase 3
77
Donepezil HydrochlorideEisaiPre-clinical
23
Lecanemab IV + Placebo + Lecanemab SCEisaiPhase 3
77